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Abstract: Neutrophil-dominated inflammation plays an important role in many airway diseases including asthma, chronic 
obstructive pulmonary disease (COPD), bronchiolitis and cystic fibrosis. In cases of asthma where neutrophil-dominated 
inflammation  is  a  major  contributing  factor  to  the  disease,  treatment  with  corticosteroids  can  be  problematic  as 
corticosteroids have been shown to promote neutrophil survival which, in turn, accentuates neutrophilic inflammation. In 
light of such cases, novel targeted medications must be developed that could control neutrophilic inflammation while still 
maintaining  their  antibacterial/anti-fungal  properties,  thus  allowing  individuals  to  maintain  effective  innate  immune 
responses to invading pathogens. The aim of this review is to describe the molecular mechanisms of neutrophil apoptosis 
and how these pathways are modulated by glucocorticoids. These new findings are of potential clinical value and provide 
further insight into treatment of neutrophilic inflammation in lung disease. 
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INTRODUCTION  
  Neutrophils are the primary line of defense for the innate 
immune  system.  These  polymorphonuclear  leukocytes  are 
produced in the bone marrow from myeloid stem cells and 
constitute  50-70%  of  white  blood  cells.  Neutrophils  in 
human  blood  are  partitioned  between  two  systems:  a)  the 
circulating  pool  and  b)  the  “marginating”  pool  which  is 
transiently  arrested  in  narrow  capillaries  primarily  in  the 
lung [1]. Neutrophils are equally distributed and constantly 
exchanged between the two systems [2]. When inflammation 
occurs,  an  active  process  of  adhesion  is  initiated  where 
neutrophils are arrested from circulating in the blood vessels 
and are guided by graded concentrations of multiple chemo-
attractants across the endothelial layer, pericyte sheath and 
basement membrane and into extravascular tissue [3]. Once 
removed from the circulating pool, neutrophils continue to 
migrate until they reach the site of inflammation.  
  Neutrophils  act  by  recognizing  pathogen  associated 
molecular patterns (PAMPs) through their germline encoded 
toll  like  receptors  (TLRs)  which  help  them  to  combat 
bacterial and fungal infections through phagocytosis and the 
release of granule contents [4]. They also express receptors 
for  antibody  (fraction  crystallizable  receptors:  FcRs)  and 
complement (CRs), and thus act in concert with many com-
ponents of the immune system to fight infection. Bacterial 
killing is usually done through phagocytosis, or the uptake of 
individual pathogens. This process involves FcγRII and CR3 
receptors that work in cooperation with  their co-receptors, 
FcγRIIIB and CR1 [5]. Once encapsulated into the phago-
some, molecules such as neutrophilic proteases and reactive 
oxygen species are used to digest the contents of the vacuole. 
Another mechanism of bacterial killing utilized by neutro-
phils  is  degranulation,  which  occurs  when  neutrophils 
release  their  pre-stored  granule  contents  to  the  outside  
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environment.  Different  types  of  granules  contain  various 
substances designed to kill target cells [5].  
  Neutrophils also have  the capacity to generate massive 
amounts of oxygen and nitrogen intermediates through “res-
piratory burst” and other mechanisms. These intermediates 
are produced as a result of the assembly and activation of 
NAPDH oxidase which reduces oxygen to superoxide anion. 
This  results  in  the  production  of  intermediates  containing 
free  radicals  that  can  be  used  to  destroy  phagocytosed 
microbes [6].  
  Finally, a novel anti-microbial mechanism of neutrophils 
has recently been characterized [7]. Neutrophil extracellular 
traps (NETs) are extracellular proteins mainly composed of 
chromatin,  with  specific  granular  components  attached  to 
them [8]. These threads form cables and three-dimensional 
“web-like”  structures,  which  are  “spat  out”  in  response  to 
cytokine-, FcR- or TLR-mediated activation [9, 10]. NETs 
have been shown to trap and kill both bacteria and fungi [7]. 
It should be noted that NET formation is also a form of cell 
death that does not implicate caspases or DNA fragmentation 
as in apoptosis [10].  
  All  of  the  above  mentioned  neutrophilic  activities  are 
modulated by specific regulatory molecules. Cytokines such 
as  tumor  necrosis  factor-α  (TNF-  α),  interleukin  (IL)-1β, 
granulocyte-colony  stimulating  factor  (G-CSF)  and  granu-
locyte-macrophage colony stimulating factor (GM-CSF) and 
chemokines such as IL-8 have profound effects on neutro-
phils. They amplify several responses such as adhesion and 
respiratory burst [5]. It has now been accepted that neutro-
phils  are  not  only  the  target  of,  but  are  also  a  source  of 
various  cytokines  and  chemokines  [11].  Although  neutro-
phils were long  considered to be devoid of  transcriptional 
activity,  new  evidence  suggests  that  neutrophils  constitu-
tively  or  inducibly  synthesize  and  release  these  mediators 
[12].  
  Lastly, it is important that neutrophils have the ability to 
discriminate between pathogenic and harmless antigens [13]. 
Antibodies, complement molecules and cytokines all affect 
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distinguishing  the  “self”  from  the  “non-self”  and  deter-
mining the course and intensity of the general immune res-
ponse.  Considering  the  aggressive  nature  of  neutrophils,  a 
non-specific  response  can  cause  damage  to  healthy  tissue. 
When  regulatory  processes  that  control  recruitment,  acti-
vation and apoptosis are impaired, neutrophils may become 
the predominant contributor to tissue injury [5]. 
NEUTROPHILS  AND  AIRWAY  INFLAMMATORY 
DISEASES  
  Inflammation, and chronic persistence of granulocytes in 
tissue, is now recognized as a central process in the patho-
genesis  of  diseases  such  as  COPD  and  bronchial  asthma 
[14]. In inflammation, the potential for neutrophils to cause 
tissue  damage  via  the  release  of  toxic  reactive  oxygen 
species and granule enzymes such as proteases is very high. 
For  example,  it  has  been  reported  in  the  airways  that 
secondary necrosis of apoptotic neutrophils leads to release 
of  cytotoxic  granules,  causing  harm  to  resident  structural 
cells [15]. 
  Although glucocorticoids are generally considered to be 
the  treatment  of  choice  in  many  inflammatory  diseases, 
glucocorticoid resistance in diseases such as asthma [16, 17], 
COPD [18], septic shock [19], idiopathic pulmonary fibrosis 
[20] and others has been associated with neutrophilic inflam-
mation.  It  is  known  that  neutrophilic  asthma  represents  a 
fairly large proportion of the disease overall, up to 50% by 
some reports [21]. Although glucocorticoids lead to marked 
reduction of eosinophils, mast cells, T lymphocytes and mac-
rophages  in  sputum,  bronchoalveolar  lavage  and  bronchial 
wall [21], changes in the neutrophilic components of asthma 
are often the opposite, with reports of increase in neutrophils 
after glucocorticoid therapy [22, 23].  
  The functional longevity of neutrophils at inflamed sites 
is  generally  controlled  by  apoptosis  [14].  In  treatment  of 
asthma, clinical improvement is associated with granulocyte 
apoptosis and appearance of apoptotic bodies within airway 
macrophages [24]. As such, understanding the processes that 
regulate constitutive and delayed neutrophil apoptosis may 
assist in identifying new therapeutic targets [25]. 
NEUTROPHIL APOPTOSIS 
  In  the  immune  system,  a  fine  balance  is  constantly 
maintained between apoptosis and proliferation of immune 
cells. Apoptosis plays an important role by preventing over-
activation of immunity, consequently avoiding self-inflicted 
pathology.  Once  neutrophil  apoptosis  has  occurred,  the 
apoptotic cells are recognized and phagocytosed by macro-
phages.  This  prevents  the  release  of  potentially  harmful 
neutrophilic  substances  into  the  extracellular  environment. 
Furthermore, neutrophil elimination by macrophages is also 
associated  with  a  subsequent  release  of  anti-inflammatory 
molecules such as IL-10 and transforming growth factor-β 
[26].  During  this  process,  the  potential  for  neutrophils  to 
cause tissue damage via the release of toxic reactive oxygen 
species and granule enzymes such as proteases is lowered by 
apoptosis and inflammation is discouraged.  
  The above mentioned phenomena explain the association 
between clinical improvement in the treatment of asthma and 
granulocyte apoptosis. In other words, modulators of neutro-
phil  apoptosis  as  a  way  to  decrease  inflammation  could 
prove useful in the treatment of inflammatory lung disease. 
On  the  other hand, an excess of  apoptosis  in the  immune 
system  is  also  unfavorable  as  it  predisposes  the  host  to 
infections by destroying cells that are reactive to pathogens, 
thus providing an escape mechanism for invaders [27].  
  In the human body neutrophil apoptosis is regulated by 
multiple proteins. The most notable are caspases, the Bcl-2 
family of proteins including myeloid cell leukemia-1 (Mcl-
1), inhibitor of apoptosis proteins (IAPs), phoshatidylinositol 
3-  kinases  (PI3Ks)  and  mitogen  activated  protein  kinases 
(MAPKs).  Any  agent  (e.g.  glucocorticoids)  capable  of 
influencing the activity of these proteins may exert an effect 
on neutrophil apoptosis.  
  Caspases are cysteine proteases that carry out the final 
stages  of  apoptosis  by  cleaving  more  than  200  substrate 
proteins  at  specific  consensus  sites  [28].  Each  caspase  is 
present  constitutively  as  a  zymogen  that  must  be  proteo-
lytically cleaved in order to be activated. Caspases can be 
activated  through  either  the  extrinsic  or  intrinsic  pathway. 
The binding of death ligands to their receptors on the cell 
surface  activates  the  extrinsic  pathway  (for  example  Fas 
ligand  binding  the  Fas  receptor)  [29].  In  contrast,  the 
intrinsic  pathway  is  triggered  in  response  to  death  stimuli 
from  within  the  cell  such  as  DNA  damage  or  oncogene 
activation  [30].  The  intrinsic  pathway  is  mediated  by  the 
mitochondrion  which  releases  initiator  proteins,  namely 
cytochrome c and second mitochondria-derived activator of 
caspases (Smac) aka direct IAP binding protein with low pI 
(DIABLO). Due to the fact that these proteins are found in 
the  mitochondria,  the  release  of  caspase  activator  proteins 
depends on the permeability of the mitochondrial membrane. 
As such, the molecules responsible for controlling mitochon-
drial membrane integrity constitute the major checkpoint of 
the intrinsic pathway. They are referred to as Bcl-2 family of 
proteins.  
  There  are  around  20  members  of  the  Bcl-2  family  of 
proteins.  Bcl-2,  Bcl-xl,  Bcl-w,  myeloid  cell  leukemia-1 
(Mcl-1) and A1 are all anti-apoptotic family members. The 
major  pro-apoptotic  members  are  the  cytosolic  Bcl-2-
associated  X  protein  (Bax)  and  the  outer  mitochondrial 
membrane bound Bcl-2 homologous antagonist-killer (Bak) 
[31].  Activation  of  Bax/Bak  is  assured  by  other  pro-
apoptotic  Bcl-2  family  members  such  as  BH3  interacting 
domain death agonist (Bid). Although the specific activation 
mechanism  is  not  clear,  it  has  been  proposed  that  some 
proteins interact directly with Bax/Bak to activate them [32]. 
In another proposed mechanism, these pro-apoptotic proteins 
bind to anti-apoptotic factors thereby neutralizing their effect 
on Bax/Bak [32]. In this way, the Bcl-2 family of proteins 
interacts,  often  blocking  one  another’s  function,  and  con-
sequently the mitochondrial membrane integrity is efficiently 
controlled.  
  In an  interesting report  in 1998,  Moulding  et al.  com-
pared  the  expression  of  various  Bcl-2  family  members  in 
neutrophils. They reported a lack of Bcl-2 and Bcl-xL but an 
abundance of Mcl-1 protein [33]. Pro-survival signals such 
as cytokines and growth factors have been reported to induce 
Mcl-1  expression,  whereas  its  levels  are  down-regulated 
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proposed  for  the  induction  or  repression  of  Mcl-1  at  the 
promoter level. In GM-CSF stimulated neutrophils, the Janus 
kinase/signal  transducers  and  activators  of  transcription 
(JAK/STAT) pathways as well as PI3K are important for the 
induction  of  Mcl-1  [34].  Moreover,  IL-3  in  murine  pro-B 
cells  brings  about  PU.1  mediated  transcription  of  Mcl-1 
through activation of p38 MAPK [35]. The exact mode of 
function of Mcl-1 is not clear but it is thought to prevent loss 
of  mitochondrial  integrity  and  cytochrome  c  release.  This 
may  occur  through  heterodimerization  with  pro-apoptotic 
Bcl-2 family members such as Bim, Bak or Bax [34, 36].  
  Additional  checkpoints  for  apoptosis  include  IAPs  and 
PI3K.  IAPs  inhibit  caspase  activity  by  directly  binding  to 
them [37]. The pro-apoptotic mitochondrial proteins Smac/ 
DIABLO  and  Omi  aka  high  temperature  requirement  A2 
(HtrA2) antagonize IAPs, thus allowing caspase activity to 
pursue  [38].  Secondly,  the  PI3Ks  constitute  a  unique  and 
conserved  family  of  intracellular  lipid  kinases  that  phos-
phorylate the 3’hydroxyl group of phosphatidylinositol and 
phosphoinositides  [39].  PI3K  seems  to  function  as  a 
signaling molecule that is ubiquitously needed for survival of 
neutrophils.  Many  anti-apoptotic  agents  require  the  PI3K 
signal [4, 40-43].  
  One  last  apoptotic  checkpoint  to  be  mentioned  is  the 
MAPKs. MAPKs are a family of conserved protein kinases 
that  phosphorylate  target  protein  substrates  and  regulate  a 
number  of  cellular  activities  including  gene  expression, 
mitosis, cell movement, metabolism, cell survival and apop-
tosis.  Conventional  MAPKs  consist  of  three  family  mem-
bers: the extracellular signal-regulated kinase (ERK); the c-
Jun  NH2-terminal  kinase  (JNK);  and  the  p38  MAPK.  All 
three family members have distinct regulation and functions 
[44].  
  There is evidence that ERK, p38 and JNK MAPKs are all 
important  in  regulating  granulocyte  apoptosis  [45].  More 
specifically, it has been shown that p38 MAPK is the only 
one of the three MAPK family members that is essential for 
dexamethasone induced survival of human neutrophils [46, 
47]. Another study done by Alvarado-Kristensson et al. con-
firmed  the  anti-apoptotic  role  of  p38  MAPK  by  demons-
trating that it can phosphorylate and inactivate caspase-3 and 
caspase-8 [48]. Despite  these findings,  many other studies 
have demonstrated the pro-apoptotic effects of p38 MAPK. 
p38  MAPK  has  recently  been  shown  to  be  essential  in 
inducing  apoptosis  in  human  neutrophils  exposed  to 
Mycobacterium  tuberculosis  [49].  Taken  together,  these 
findings highlight the complexity of the regulatory processes 
that govern the  activity of  MAPKs. In fact, both p38 and 
JNK MAPK have dual pro-/anti-apoptotic roles, while ERK 
appears to be primarily important in the propagation of anti-
apoptotic  signals  [46,  47].  In  the  context  of  Dex  induced 
survival of neutrophils, the exact role of p38 MAPK remains 
unknown.  
GLUCOCORTICOIDS  AND  NEUTROPHIL  APOP-
TOSIS 
  Glucocorticoids  are  part  of  the  steroid  family  of  hor-
mones. They mediate their effect on target cells by directly 
binding  to  cytosolic  glucocorticoid  receptors  (GRs).  The 
unligated  GR  is  normally  found  in  the  cytoplasm  in  a 
complex with multiple other proteins. Binding of the ligand 
then induces release of the receptor from its protein complex, 
dimerization and translocation to the nucleus where the GR 
can regulate the expression of genes. The nuclear GR binds 
to specific sequences of nucleic acids called Glucocorticoid 
response  elements  (GRE)  in  the  promoter  region  of  res-
ponsive genes and can either induce or repress transcription 
of various molecules including inflammatory mediators [50]. 
Indirect transcriptional effects of glucocorticoids result from 
their  interaction  with  other  transcription  factors  such  as 
activating protein-1 (AP-1) and nuclear factor-κB (NF-κB) 
[51].  Glucocorticoids  can  also  have  non-transcriptional 
effects on cell activity by modulating various intra-cellular 
signaling pathways [52].  
  Perhaps  the  most  important  pharmacologic  property  of 
glucocorticoids  is  their  immunosuppressive  effect.  Gluco-
corticoids have been shown to decrease expression of pro-
inflammatory  molecules  and  increase  expression  of  anti-
inflammatory molecules [53]. They also induce apoptosis of 
thymocytes, T cells and eosinophils [54]. However, although 
glucocorticoids  are  most  notorious  for  their  apoptosis 
inducing  properties,  it  has  become  increasingly  clear  that 
they can also inhibit apoptosis and induce survival in many 
cell types  [55-70]. Various mechanisms for glucocorticoid 
mediated  inhibition  of  apoptosis  have  been  proposed  that 
include  up-regulation  of  anti-apoptotic  Bcl-2  family 
members [55, 56, 70]; stabilization [62] and induction [68] 
of  IAPs;  activation  of  NF-κB  [59,  61];  suppression  of 
components of the extrinsic pathway of apoptosis [57, 65]; 
and  induction  of  signaling  molecules  such  as  MAPK 
phosphatase-1  (MKP-1)  and  Serum  and  glucocorticoid 
activated kinase-1 (SGK-1) [63, 69] (Table 1). 
 
Table 1.  Currently Proposed Mechanisms for Glucocorticoid 
Mediated Inhibition of Apoptosis 
 
a)  Up-regulation of anti-apoptotic Bcl-2 family members [55, 56, 80]. 
b)  Stabilization and induction of IAPs [47, 61, 62].  
c)  Activation of NF-κB
  [61]. 
d)  Suppression of components of the extrinsic pathway of apoptosis [57, 
79]. 
e)  Induction of signaling molecules such as MAPK phosphatase-1 
(MKP-1) and Serum and glucocorticoid activated kinase-1 (SGK-1) 
[63, 69]. 
 
  Many  studies  have  reported  the  in  vitro  anti-apoptotic 
effect of glucocorticoids on human neutrophils [46, 47, 71-
73].  It  is  now  clear  that  glucocorticoids  including  dexa-
methasone (Dex) inhibit spontaneous neutrophil apoptosis in 
a  concentration-dependent  manner  [71-76];  the  anti-apop-
totic effect of Dex is abolished by transcription/translation 
inhibitors [72, 75] and is mediated through the GR [72, 76, 
77]; and unlike GM-CSF and lipopolysaccharide (LPS), Dex 
does not lead to activation of neutrophils, as measured by IL-
8 and superoxide production [71]. 
  There have been a number of mechanisms proposed so 
far for the above described phenomenon of glucocorticoid-
mediated  survival  specific  to  neutrophils.  One  common 
theory is that the dominant negative GRβ isoform, which is 
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interferes  with  GRα  mediated  expression  of  pro-apoptotic 
genes. The GRβ isoform has no transcriptional activity, lacks 
the  ability  to  bind  ligands  and  inhibits  GRα  activity  [78] 
which could explain the unique neutrophil response to Dex 
stimulation.  However,  current  results  argue  against  trans-
repression  of  pro-apoptotic  genes  as  a  mechanism  for 
glucocorticoid mediated survival [46, 47]. 
  In 2004, Chang et al. [79] found that bovine neutrophils 
treated with Dex demonstrated a decreased expression of Fas 
mRNA  and  protein,  which  correlated  with  decreased 
caspase-8 activity in these cells. Thus, the inhibition of the 
extrinsic pathway of apoptosis is a possible contributor to the 
glucocorticoid effect. In 2005, Madsen-Bouterse et al. [80] 
observed an increase of anti-apoptotic A1 and a decrease of 
pro-apoptotic Bak in Dex treated bovine neutrophils. These 
findings correlated with decreased activity of caspase-9, and 
were  proposed  as  another  possible  mechanism  of  gluco-
corticoid-mediated survival. 
  Lastly, a few reports have confirmed the up regulation of 
Mcl-1 in neutrophils as a result of Dex stimulation [46, 47, 
81].  Interestingly,  up-regulation  of  the  short  pro-apoptotic 
splice variant of Mcl-1 has not been observed. It has also 
been  demonstrated  that  Mcl-1  anti-sense  oligonucleotides 
abolish  Dex-induced  Mcl-1  expression  and  survival  in 
human neutrophils [81]. 
MECHANISM  OF  GLUCOCORTICOID-MEDIATED 
NEUTROPHIL SURVIVAL 
  It  has  been  suggested  that  glucocorticoids  affect 
neutrophil  apoptosis  by  suppressing  various  pro-apoptotic 
molecules.  However,  selective  induction  of  the  trans-
repressive function of GR by the GR modulator Compound 
A  (CpdA)  does  not  alter  neutrophil  apoptosis,  suggesting 
that trans-repression is not responsible for the glucocorticoid 
effect [82]. Moreover, it has been observed that, in human 
neutrophils, the levels of pro-apoptotic proteins such as Fas, 
FasL, Bid and Bax are not significantly decreased following 
stimulation with Dex [46, 47]. Furthermore,  the  inhibitory 
impact of Dex on neutrophil apoptosis cannot be considered 
uniquely  non-genomic,  since  the  effect  is  abrogated  by 
transcription/translation inhibitors [50, 83]. Consequently, it 
is now generally agreed that Dex does not act by decreasing 
pro-apoptotic factors [42, 81, 84, 85], but instead increases 
anti-apoptotic factors such as Mcl-1 and IAPs through trans-
activation (Fig. 1).  
  Mcl-1  is  the  sole  anti-apoptotic  member  of  the  Bcl-2 
family  consistently  detected  in  human  neutrophils  at  the 
protein  level  [25].  It  has  previously  been  observed  that 
glucocorticoids  can  inhibit  apoptosis  by  enhancing  anti-
apoptotic Bcl-2 family members [55, 56, 70]. For instance, 
Sivertson et al. [81] have detected increases in Mcl-1 mRNA 
 
Fig. (1). A schematic model of glucocorticoid induced survival of human neutrophil. 
Following treatment of neutrophils with dexamethasone, the latter binds to GR inducing release of the receptor from its protein complex, 
dimerization and translocation to the nucleus where it can up regulate Mcl-1 and XIAP expression. The net effects are maintenance of 
mitochondrial integrity and suppression of caspases. GR also modulates P38 and PI3K activation that may influence Mcl-1 expression or 
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and protein in Dex treated human neutrophils.  The  conse-
quence  of  the  up-regulation  of  Mcl-1  is  seen  at  the 
mitochondrial level, as Mcl-1 is an inhibitor of Bax, a pro-
apoptotic  Bcl-2  family  member  that  mediates  the  loss  of 
mitochondrial membrane integrity. In this way, glucocorti-
coids are able to regulate apoptosis at the mitochondrial level 
(Fig. 1). In addition, many studies have confirmed the impor-
tance of PI3K and p38 MAPK in neutrophils and other cell 
types that respond to pro-survival agents by enhancing Mcl-1 
[34, 35, 86].  
  Another  family  of  proteins  up-regulated  as  a  result  of 
glucocorticoid stimulation is the IAP family, which prevent 
caspase/Smac activity [37]. It has been shown that the level 
of XIAP, the prototypic IAP, can be maintained by gluco-
corticoids [46, 47, 87, 88]. This may partially account for the 
decreased activity of caspase-3 in neutrophil cultures [47].  
  It remains to be established whether glucocorticoids lead 
to direct activation of p38 MAPK and PI3K in neutrophils as 
it has been shown for GM-CSF [34, 47]. However, it is clear 
that  Dex  induced  survival  of  neutrophils  is  suppressed  by 
blocking PI3K and p38 but not JNK or  ERK  MAPK [34, 
47].  It  has  been  observed  that  the  effect  of  Dex  on  both 
neutrophil survival and Mcl-1 enhancement is dependent on 
protein  translation  and  signaling  through  PI3K  and  p38 
MAPK [47] (Fig. 1). These findings indicate a role for PI3K 
and p38 MAPK in the translation dependent enhancement of 
Mcl-1 by Dex; however, these signaling pathways also have 
alternative translation-independent anti-apoptotic effects that 
may in fact contribute to glucocorticoid-mediated neutrophil 
survival. For instance, p38 has been shown to phosphorylate 
and deactivate caspases-3 and 8 [48]; and PI3K-initiates pro-
survival phosphorylation of Bad, Bax and caspase-9 [89, 90]. 
Thus,  glucocorticoids  may  also  exert  non-transcriptional 
effects through these signaling pathways.  
CONCLUSION 
  In asthma, corticosteroids have been shown to increase 
airway  tissue  neutrophils  [23,  91].  They  have  also  been 
shown  to  decrease  chemotactic  factors  for  T  cells  and 
eosinophils but not neutrophils in asthmatic airway mucosa 
[92]. Furthermore, glucocorticoids are reportedly inefficient 
in controlling increased neutrophil matrix metalloproteinase 
(MMP) in severe asthma. Thus, glucocorticoids alone may 
not be sufficient to manage certain asthma cases, particularly 
those characterized by neutrophil-dominated inflammation.  
  From  a  physiological  point  of  view,  the  neutrophilic 
reaction  that  follows  in  vivo  glucocorticoid  administration 
may have developed as a response to stress that boosts the 
innate  immunity.  For  instance,  it  has  been  shown  that 
although increased levels of corticosteroids in mice lead to a 
decrease  in  the  lymphocyte  population  and  suppression  of 
the  adaptive  immune  response,  it  increases  neutrophil 
numbers  and  enhances  anti-bacterial  immunity.  Mice  with 
increased  serum  glucocorticoids  that  were  exposed  to  L. 
monocytogenes  and  S.  pneumonia  demonstrated  enhanced 
clearance of these bacterial infections [93].  
  Future studies are required in order to further clarify the 
mechanisms responsible for glucocorticoid induced survival 
of  neutrophils.  Determining  the  non-genomic  effects  of 
glucocorticoids, such as phosphorylation/dephosphorylation 
of  key  cellular  proteins,  or  specifying  the  pathways 
downstream and upstream of PI3K/p38 MAPK may prove 
useful. It may also be helpful to identify the gene targets of 
glucocorticoids  in  neutrophils  and  to  learn  how  induction/ 
repression of such genes impacts cellular function. Finally, 
one could even go a step further and assess the importance of 
the  above  mechanisms  in  survival  mediated  by  other 
glucocorticoid drugs available.  
  Taken  together,  the  observations  presented  previously 
provide a  model  in which Dex-mediated  inhibition of pri-
mary  human  neutrophil  apoptosis  is  associated  with  inc-
reased  levels  of  Mcl-1  and  XIAP.  Up-regulation  of  these 
molecules  correlates  with  suppression  of  various  down-
stream  pathways  of  apoptosis.  These  mechanisms  may  be 
initiated  by  GR-mediated  trans-activation  of  anti-apoptotic 
genes independently of, or in association with, intra-cellular 
signaling  molecules  and  transcription  factors.  Collectively, 
the above results underline mechanisms through which cor-
ticosteroids  undesirably  modulate  apoptosis  of  an  inflam-
matory  cell.  Development  of  GR  ligands  that  selectively 
inhibit  neutrophil  inflammatory  function  without  inducing 
survival is thus warranted. 
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